Nanjing Chia-tai Tianqing Pharmaceutical
Quick facts
Marketed products
- succinylated gelatin injection · Critical Care / Anesthesia
Succinylated gelatin acts as a plasma volume expander by increasing colloid osmotic pressure to restore intravascular fluid volume.
Phase 3 pipeline
- NTQ1062+Fulvestrant · Oncology
NTQ1062 is a selective estrogen receptor degrader (SERD) combined with fulvestrant, an estrogen receptor antagonist, to block estrogen signaling in hormone receptor-positive breast cancer. - Obeticholic Acid Tablets（OCA） · Hepatology / Gastroenterology
Obeticholic acid is a farnesoid X receptor (FXR) agonist that reduces bile acid synthesis and improves liver function by modulating nuclear receptor signaling. - Placebo + fulvestrant · Oncology
Fulvestrant is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, while placebo serves as a control arm in this combination study.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Nanjing Chia-tai Tianqing Pharmaceutical portfolio CI brief
- Nanjing Chia-tai Tianqing Pharmaceutical pipeline updates RSS
Frequently asked questions about Nanjing Chia-tai Tianqing Pharmaceutical
What are Nanjing Chia-tai Tianqing Pharmaceutical's marketed drugs?
Top marketed products include succinylated gelatin injection.
What is Nanjing Chia-tai Tianqing Pharmaceutical's pipeline?
Nanjing Chia-tai Tianqing Pharmaceutical has 3 drugs in Phase 3, 0 in Phase 2, 5 in Phase 1. Late-stage candidates include NTQ1062+Fulvestrant, Obeticholic Acid Tablets（OCA）, Placebo + fulvestrant.
Related
- succinylated gelatin injection · Critical Care / Anesthesia
- Sector hub: All tracked pharma companies